Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: a network meta-analysis of randomized, controlled trials

Ahmed M. Shaman, Brendan Smyth, Clare Arnott, Suetonia C. Palmer, Anastasia S. Mihailidou, Meg J. Jardine, Martin P. Gallagher, Vlado Perkovic, Min Jun*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    Background and objectives Elevated BP is an important risk factor for cardiovascular disease, with a prevalence of over 80% in patients undergoing maintenance dialysis. We assessed the comparative BP-lowering efficacy and the safety of BP-lowering drugs in patients undergoing maintenance dialysis. Design, settings, participants, & measurements We performed a frequentist random effects network meta-analysis of randomized, controlled trials evaluating BP-lowering agents in adult patients undergoing maintenance dialysis. Electronic databases (CENTRAL, MEDLINE, and Embase) were systematically searched (up to August 2018) for relevant trials. The main outcome was systolic BP reduction. Results Forty trials (4283 participants) met our inclusion criteria. Angiotensin-converting enzyme inhibitors, β-blockers, calcium-channel blockers, and aldosterone antagonists lowered systolic BP to a greater extent than placebo, with effect sizes ranging from-10.8 mm Hg (95% confidence interval,-14.8 to-6.7 mm Hg) for the aldosterone antagonists to-4.3 mm Hg (95% confidence interval,-7.2 to-1.5 mm Hg) for angiotensin-converting enzyme inhibitors. Aldosterone antagonists and b-blockers were superior to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, and renin inhibitors at lowering systolic BP. Compared with angiotensin-converting enzyme inhibitors, aldosterone antagonists and β-blockers lowered systolic BP by 6.4 mm Hg (95% confidence interval,-11.4 to-1.4 mm Hg) and 4.4 mm Hg (95% confidence interval,-7.4 to-1.3 mm Hg), respectively. Systolic BP reduction was not different with angiotensin receptor blockers, α-blockers, and calcium-channel blockers compared with angiotensin-converting enzyme inhibitors. Renin inhibitors were less effective. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists incurred risks of drug discontinuation due to adverse events and hypotension. Conclusions BP-lowering agents significantly reduced systolic BP in patients undergoing maintenance dialysis. b-Blockers and aldosterone antagonists may confer larger reductions, although treatment with aldosterone antagonists may be limited by adverse events.

    Original languageEnglish
    Pages (from-to)1129-1138
    Number of pages10
    JournalClinical Journal of the American Society of Nephrology
    Volume15
    Issue number8
    DOIs
    Publication statusPublished - 7 Aug 2020

    Fingerprint

    Dive into the research topics of 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: a network meta-analysis of randomized, controlled trials'. Together they form a unique fingerprint.

    Cite this